Transaction Overview

•3SBio announced the closing of the licensing agreement between its subsidiary Sunshine Guojian and Syncromune to develop and commercialize the anti-PD-1 antibody 609A worldwide.

•三生制药旗下子公司三生国健药业将其研发品种609A（抗PD-1人源化单克隆抗体注射液）全球权益授权给美国Syncromune公司。

•Sunshine Guojian will receive an upfront cash payment and regulatory milestones of several million and royalties on future sales.

•三生国健将有望基于609A的临床价值前景、重要监管及销售里程碑，以及其他商业化价值，获得数亿美元的首付款、里程碑付款及其他的激励。

•YAFO Capital (Shanghai) acted as financial advisors on this transaction for Syncromune.

•雅法资本担任本次交易Syncromune的财务顾问。

(January , 2022, Shanghai, China) 3SBio (HKEX: 01530), one of the leading biopharmaceutical companies in China today announced the closing of the licensing agreement between its subsidiary Sunshine Guojian （stock code：688336）and Syncromune to develop and commercialize Sunshine Guojian’s anti-PD-1 antibody 609A for use with syncrovax™ immuno-oncology combination therapy worldwide. As part of the partnership, Sunshine Guojian has the potential to receive hundreds of millions of US dollars in payments including: an upfront cash payment that reflects the projected clinical value of the PD-1 molecule, significant regulatory and sales milestones and other incentives based on the long-term commercial value of the patented PD-1 molecule. YAFO Capital (Shanghai) acted as exclusive financial advisors on this transaction for Syncromune.

（2022年1月4日，中国上海）中国生物制药领军企业三生制药（01530.HK）近日宣布，旗下子公司三生国健药业（上海）股份有限公司（证券代码：688336）签署授权协议，将其研发品种609A（抗PD-1人源化单克隆抗体注射液）用于肿瘤免疫联合疗法syncrovax™的全球权益授权给美国Syncromune公司。根据协议，三生国健将有望基于609A的临床价值前景、重要监管及销售里程碑，以及其他商业化价值，获得数亿美元的首付款、里程碑付款及其他的激励。雅法资本担任本次交易Syncromune的财务顾问。

Under the terms of the agreement, Syncromune will acquire the global development and commercialization right of 609A for its syncrovax™ immuno-oncology therapy. Milestone payments and royalties will be based on syncrovax™ total sales. Sunshine Guojian still holds all the global rights beyond syncrovax™.

根据协议条款，Syncromune公司获得将609A用于其肿瘤免疫疗法syncrovax™的全球开发及商业化权益。三生国健销售分成及里程碑收入将源自syncrovax™联合疗法的销售总金额，同时三生国健将继续保有609A全球任何syncrovax™疗法以外的权益。

609A is an anti-PD-1 antibody developed by Sunshine Guojian, phase 1 trial in the US has been finished and phase 2 trial in China is ongoing. Public documents show that 609A has stronger anti-tumor potency than Keytruda and Opdivo in animal models.

609A为三生国健研发的一款中美双报的抗PD-1人源化单抗，美国已完成I期临床，国内已进入II期临床阶段。根据公开资料，609A在早期动物模型的数据显示出比Keytruda和Opdivo更强的抗肿瘤活性。

According to preclinical studies, 609A has explicit molecular structure, good DP stability and activity, PK/PD results equal or outperform other drugs in the same class. “609A is the first innovative drug product of 3SBio to go overseas. We are very happy to cooperate with Syncromune. This transaction will not only bring cash flow and income to the company, but also it will have a positive impact on 609A's future cooperation with foreign countries and domestic clinical research and registration approval, and at the same time demonstrates 3SBio's R&D strength," said Dr. Jing Lou, Chairman of 3SBio.

“临床前研究结果显示，609A的分子结构明确，产品稳定性良好，药物活性、动物药物代谢动力学（PK）/药物效应动力学（PD）均达到或超过了国外同类药物。”三生国健董事长娄竞博士表示，“609A是三生国健首个出海的创新药产品，我们很高兴能与Syncromune公司合作。本次交易除为公司带来现金流和收益外，也为609A未来的对外合作及国内的临床研究和注册审批带来了积极的影响，同时彰显了三生国健的研发实力。”

About 609A

609A is an anti-PD-1 humanized monoclonal antibody developed by Sunshine Guojian. It targets the same target with two imported drugs (Keytruda and Opdivo), but has different amino acid sequences. In the humanized PD-1 mouse model, it showed stronger tumor activity than Keytruda and Opdivo. The results of in vivo and in vitro comparisons indicate that SSGJ-609A is similar to the two imported drugs in terms of biological activity, efficacy, pharmacokinetics, etc.; preclinical research results show that 609A has a clear molecular structure and good product stability, Drug activity, animal pharmacokinetics (PK)/pharmacodynamics (PD) have reached or surpassed similar foreign drugs.

609A 是三生国健研发的一款中美双报的抗PD-1人源化单抗，与已上市的两种进口药物（Keytruda和Opdivo）针对相同靶点，但具有不同的氨基酸序列，在人源化PD-1小鼠模型中显示出较Keytruda和Opdivo更强的肿瘤活性。体内外比对研究结果表示，SSGJ-609A在包括生物活性、药效、药代等各方面与两种进口药物均具有相似性；临床前研究结果显示，609A的分子结构明确，产品稳定性良好，药物活性、动物药物代谢动力学（PK）/药物效应动力学（PD）均达到或超过了国外同类药物。

About 3SBio

3SBio Inc. is a leading bio-pharmaceutical company integrating research and development (“R&D”), production and sales, with a focus on improving the life quality of patients with high quality medicines to benefit human health. At present, the Company owns more than 100 national invention patents and has launched more than 30 kinds of products into the market, covering several treatment fields, including, among others, cancer, autoimmune, kidney disease, metabolism and dermatology. The Company owns four R&D centers of the National Engineering Research Center of Antibody Medicine and dual platforms for biopharmaceutical and chemical medicine. There are 35 kinds of products under R&D, 24 kinds of them are the innovative new drugs. The Group also owns five production bases complying with the GMP standards. In the future, 3SBio Inc. will continue to uphold the concept of “Care for Life, Cherish Life, Create Life” to create a world-leading biopharmaceutical company in China. Please visit www.3sbio.com for additional information

三生制药是一家集研发、生产和销售为一体的生物制药领军企业，致力于以高品质的药品提高患者生存质量，为人类健康造福。目前，公司拥有100余项国家发明专利授权，30余种上市产品，覆盖肿瘤、自身免疫、肾病、代谢及皮肤科等治疗领域。公司拥有抗体药物国家工程研究中心以及生物药和化药双平台的4大研发中心，共有35种在研产品，其中24种为创新药物，并拥有符合GMP标准的5大生产基地。未来，三生制药将继续秉持“珍爱生命、关注生存、创造生活”的理念，全力打造全球领先的中国生物制药企业。请访问www.3sbio.com获取更多信息。

About Syncromune

Syncromune is an innovative biopharmaceutical company headquartered in the United States, focusing on the development of a new generation of tumor immunotherapy for intratumoral drug delivery. The core technology syncrovax™ therapy is a personalized autologous vaccine platform intended to overcome the immunosuppressive properties of metastatic cancer to solve the limitations of current systemic immunotherapy, so as to achieve the purpose of treating a variety of solid tumors.

Syncromune是总部在美国的创新生物制药公司，专注于新一代瘤内给药的肿瘤免疫疗法的开发。核心技术 syncrovax™疗法为个性化的自体疫苗平台，致力于通过克服转移性癌症的免疫抑制特性，来解决当前系统免疫疗法的局限性，从而实现对多种实体瘤的治疗目的。

About YAFO Life Sciences

YAFO Life Sciences (YLS) is the healthcare division of YAFO Capital, which is focused on helping leading U.S. and European biopharma and MedTech companies to successfully enter the Asian market, especially in China and Japan. YLS also helps domestic pharma companies in global market research, targeting, and negotiation. Along with our local partners, YLS is dedicated to bridging the gap between global medical technologies and the Asian market. For more information regarding YAFO, go to: www.yafocapital.com

雅法全球医疗（YAFO Life Sciences）是雅法资本旗下的医疗大健康部门。专注于帮助具有“中国角度”的海外医药企业在中国的授权、战略合作及融资；以及为中国创新药企业提供海外市场授权机会、海外市场咨询、寻找和引进海外标的服务。我们致力于成为全球医疗技术对接中国市场与资本的桥梁。目前海外有超过三十位资深合伙人，深度覆盖美国、欧洲、日本、韩国等全球医疗创新区域。

Contact

Wendi Xiang  相文迪

Vice President

wxiang@yafocapital.com

联系我们：相文迪    Vice President ，wxiang@yafocapital.com